194 related articles for article (PubMed ID: 18183589)
21. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
22. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
[TBL] [Abstract][Full Text] [Related]
23. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
24. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Wang X; Gérard C; Thériault JF; Poirier D; Doillon CJ; Lin SX
J Mol Cell Biol; 2015 Dec; 7(6):568-79. PubMed ID: 25966904
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
26. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
Konings GF; Cornel KM; Xanthoulea S; Delvoux B; Skowron MA; Kooreman L; Koskimies P; Krakstad C; Salvesen HB; van Kuijk K; Schrooders YJ; Vooijs M; Groot AJ; Bongers MY; Kruitwagen RF; ; Romano A
J Pathol; 2018 Feb; 244(2):203-214. PubMed ID: 29144553
[TBL] [Abstract][Full Text] [Related]
27. Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women.
Luu-The V; Tremblay P; Labrie F
Mol Endocrinol; 2006 Feb; 20(2):437-43. PubMed ID: 16166196
[TBL] [Abstract][Full Text] [Related]
28. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Husen B; Huhtinen K; Saloniemi T; Messinger J; Thole HH; Poutanen M
Endocrinology; 2006 Nov; 147(11):5333-9. PubMed ID: 16916945
[TBL] [Abstract][Full Text] [Related]
29. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
30. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
31. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Liu ZJ; Lee WJ; Zhu BT
Cancer Res; 2005 Jul; 65(13):5802-11. PubMed ID: 15994956
[TBL] [Abstract][Full Text] [Related]
32. Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown.
Han H; Thériault JF; Chen G; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():36-45. PubMed ID: 28554725
[TBL] [Abstract][Full Text] [Related]
33. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
[TBL] [Abstract][Full Text] [Related]
34. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
35. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
[TBL] [Abstract][Full Text] [Related]
36. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
[TBL] [Abstract][Full Text] [Related]
37. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
38. Crystal structures of human 17β-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP
Li T; Stephen P; Zhu DW; Shi R; Lin SX
FEBS J; 2019 Jun; 286(11):2155-2166. PubMed ID: 30768851
[TBL] [Abstract][Full Text] [Related]
39. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
40. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
